Richard Chin, MD
Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Richard has developed several drugs for immune diseases, including Lucentis®, Xolair®, Tysabri®, and Rituxan®. These products have yielded over $10 billion in sales per year.
Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech, where he oversaw Genentech’s drug development programs; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. In 2006, BusinessWeek named Richard one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.
Hangjun Zhan, PhD
Dr. Zhan is a highly regarded protein biochemist and biophysicist with 20 years of drug discovery experience in the biotechnology industry. He joined KindredBio in February 2014 to lead our biologics research. Most recently, Dr. Zhan served as an Executive Member at Aragen Biosciences and led their protein sciences group. Prior to that, Dr. Zhan established and led the Protein Biochemistry Group at Exelixis, including Protein Expression, Fermentation/Bioproduction, Protein Purification/Biophysics, and Proteomics. His team’s work led to more than 20 drug candidates. Prior to that, Dr. Zhan was Group Leader of Protein Chemistry at Axys Biopharmaceuticals (Celera), where he managed a fermentation group and a protein biochemistry group. Dr. Zhan completed his post-doctoral training in Dr. John Collier’s lab at Harvard Medical School, where he applied in-depth biophysics to elucidate dynamic protein structural changes in solution and in membrane. While earning his Ph.D. from the University of Washington, he discovered a novel chemical-signaling molecule involved in bacterial invasion.